Impact of Protect Your Colon™ on CRC Screening
Launched by CEDARS-SINAI MEDICAL CENTER · Jun 30, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the impact of a tool called Protect Your Colon™, which helps people make informed decisions about colorectal cancer (CRC) screening. The goal is to see if this decision aid can encourage more individuals to get screened for CRC by improving communication about screening options and aligning the tests with what patients value. Researchers believe that by using Protect Your Colon™, people will be more likely to understand their screening choices and ultimately decide to get screened.
To participate, individuals should be between 45 and 75 years old and either have never been screened for CRC or are not up-to-date with their screenings. It's important that they are not at high risk for CRC due to factors such as family history or certain medical conditions. Participants will be randomly assigned to receive either the Protect Your Colon™ tool or usual care, allowing researchers to compare the effectiveness of this new approach. Those who join the study can expect to engage in discussions about their screening options and make choices that suit their personal preferences.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals 45 to 75 years old
- • No prior CRC screening or not up-to-date with CRC screening
- • Not at high risk for CRC (e.g., inflammatory bowel disease, colon polyposis syndromes, family history of CRC)
- Exclusion Criteria:
- • Does not speak English
- • Does not have internet access
- • Any records flagged "break the glass" or "research opt out."
About Cedars Sinai Medical Center
Cedars-Sinai Medical Center is a renowned nonprofit academic medical center located in Los Angeles, California, recognized for its commitment to patient care, research, and education. As a leading institution in clinical trials, Cedars-Sinai harnesses innovative approaches to advance medical knowledge and improve treatment outcomes across various specialties. With a multidisciplinary team of experts, state-of-the-art facilities, and a patient-centered approach, Cedars-Sinai actively contributes to the development of novel therapies and interventions, ensuring the highest standards of clinical research while prioritizing patient safety and ethical considerations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Christopher V Almario, MD, MSHPM
Principal Investigator
Cedars-Sinai Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported